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Abstract
Background
Cardiovascular disease is the major cause of death in renal transplant recipients (RTRs)
and linked to arterial calcification. The calcium-sensing receptor (CaSR), a G-protein cou-
pled receptor, plays a pivotal role in extracellular calcium homeostasis and is expressed in
the intimal and medial layers of the arterial wall. We investigated whether common CASR
gene variants are predictors for aortic and coronary artery calcification or influence risk fac-
tors such as serum calcium, phosphate and glucose concentrations in RTRs.
Methods
Two hundred and eighty four RTRs were investigated for associations between three CASR
promoter region single nucleotide polymorphisms (SNPs) (rs115759455, rs7652589,
rs1501899), three non-synonymous CASR coding region SNPs (A986S, R990G, Q1011E),
and aortic and coronary artery calcium mass scores, cardiovascular outcomes and calcifi-
cation risk factors that included serum phosphate, calcium, total cholesterol and glucose
concentrations.
Results
Multivariate analysis revealed that RTRs homozygous for the minor allele (SS) of the
A986S SNP, when compared to those homozygous for the major allele (AA), had raised
serum glucose concentrations (8.7±5.4 vs. 5.7±2.1 mmol/L, P<0.05). In addition, RTRs
who were heterozygous (CT) at the rs115759455 SNP, when compared to those
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homozygous for the major allele (CC), had higher serum phosphate concentrations (1.1±
0.3 vs. 1.0±0.2 mmol/L, P<0.05). CASR SNPs were not significant determinants for aortic
or coronary artery calcification, and were not associated with cardiovascular outcomes or
mortality in this RTR cohort.
Conclusions
Common CASR SNPs may be independent predictors of serum glucose and phosphate
concentrations, but are not determinants of vascular calcification or cardiovascular
outcomes.
Introduction
Cardiovascular disease is the major cause of premature death in renal transplant recipients
(RTRs) [1]. Cardiovascular events and mortality in RTRs are strongly linked to the presence of
substantial vascular calcification, which affects> 30% of transplanted patients [2]. Vascular
calcification is an active disease process characterised by mineral deposition within the medial
and intimal layers of the arterial wall [3, 4]. Medial calcification is a consequence of dysregu-
lated systemic mineral homeostasis and associated with the trans-differentiation of vascular
smooth muscle cells (VSMCs) in the arterial media to osteochondrocytic cells that release ma-
trix vesicles, which act as a nidus for mineralisation in the presence of elevated circulating calci-
um and/or phosphate concentrations. [4]. Medial calcification reduces the compliance of large
arteries such as the thoracic aorta, thereby leading to hypertension and left ventricular dysfunc-
tion [5]. Intimal calcification develops within atherosclerotic plaques, and is the major form of
mineral deposition within the coronary arteries [6]. Thus, the presence of intimal calcification
is an indicator of advanced atherosclerosis and associated with myocardial infarction [7].
Major risk factors for atherosclerotic plaque development and intimal calcification include ele-
vations in serum total cholesterol and glucose concentrations, together with increased systolic
blood pressure [8].
Arterial calcification has been reported to have a substantial genetic component [9, 10], and
previous studies have demonstrated associations with common polymorphisms in genes en-
coding inhibitors of blood vessel mineralisation such as fetuin A and matrix Gla protein [11,
12]. However, the contribution to vessel calcification from polymorphisms of the calcium-sens-
ing receptor (CaSR), which is a G-protein coupled receptor (GPCR) that plays a pivotal role in
systemic mineral homeostasis through its effects on parathyroid hormone (PTH) secretion and
renal tubular calcium reabsorption [13], has not been investigated. Moreover, the CaSR is ex-
pressed and functionally active in the intimal and medial layers of large elastic arteries such as
the aorta, and muscular arteries such as the coronary, tibial and internal mammary arteries
[14–17], and abnormal functioning of the arterially expressed CaSR has been implicated in the
trans-differentiation of VSMCs to mineralising cells, and development of vessel wall calcifica-
tion [17]. We therefore hypothesised that CASR variants may be determinants for arterial me-
dial and intimal calcification, and calcification risk factors that include serum calcium, glucose
and phosphate concentrations, in high risk patient groups such as RTRs, and selected six single
nucleotide polymorphisms (SNPs) (3 non-synonymous coding region SNPs and 3 promoter
region SNPs) (Fig. 1), five of which have been previously associated with indices of mineral me-
tabolism and/or cardiovascular disease [18–22]. We investigated a well characterised cohort of
RTRs [2, 23] for associations between these CASR SNPs and cardiovascular outcomes,
CASR SNPs and Vascular Calcification
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mortality, coronary artery calcification (CAC) and aortic calcification (AoC), and vascular cal-
cification risk factors, which included: systolic blood pressure, serum calcium, phosphate, total
cholesterol and glucose concentrations.
Materials and Methods
Patients
Patients were ascertained from the Brussels Renal Transplant Cohort [2, 23], which was col-
lected between February 3rd 2004 and January 27th 2005, and comprised>280 RTRs that had
an isolated kidney graft functioning for>1 year. The study protocol was approved by The Eth-
ics Committee of the Université catholique de Louvain (UCL) Medical School, Brussels and
written informed consent was obtained from all patients [2].
Clinical parameters
At baseline, clinical parameters including a history of cardiovascular events (defined as myo-
cardial infarction, cerebrovascular event or transient ischaemic attack, and lower limb necrosis
or revascularisation) were recorded by a review of the medical charts. Blood samples were ob-
tained at inclusion for biochemical analysis. Serum creatinine, total calcium, phosphate, glu-
cose and total cholesterol concentrations were measured using a Synchron CX analyzer
(Beckman Coulter). Serum intact PTH concentrations were measured by a two-site immunora-
diometric method (Nichols Institute), and serum 25-hydroxyvitamin D and 1,25-dihydroxyvi-
tamin D concentrations were measured using a LIAISON analyzer (Diasorin Inc). At
inclusion, calcification of the aorta and the main coronary arteries were assessed by multi-slice
spiral CT scanning of the chest on a 16-slice scanner (Brillance 16; Philips Healthcare, http://
www.healthcare.philips.com), as described [2]. The calcium mass of the thoracic aorta and the
4 branches of the main coronary arteries were scored individually, as previously described [2].
Agatston scores and amount of hydroxyapatite (mg) of the coronary arteries and thoracic aorta
were measured using a manufacturer algorithm (Heart Beat CS; Philips Healthcare) and by a
single operator. Intra-operator variability was 3% and 8%, respectively, for CAC and AoC [2].
Fig 1. Schematic representation of the genomic organisation of theCASR showing location of the six SNPs selected for analysis. TheCASR gene
consists of 8 exons (1a, 1b, 2–7). The start (ATG) and stop (TGA) codons are in exons 2 and 7, respectively. Exons 1a, 1b, the 5’ portion of exon 2, and the 3’
portion of exon 7 are untranslated. The 3’ portion of exon 2, exons 3, 4, 5, 6 and the 5’ portion of exon 7, encode the extracellular domain (light grey), and the
mid portion of exon 7 encodes the transmembrane (dark grey) and intracellular (black) domain. Three of the six SNPs are located in the CASR promoter
region. rs115759455 and rs7652589 are located 13kbp upstream from the TATA box of promoter 1 (P1) and rs1501899 is located 4.6kbp downstream of
promoter 2 (P2). The remaining three SNPs (rs1801725, rs1042636 and rs1801726) encoding single amino acid substitutions (A986S, R990G and Q1011E,
respectively) are clustered in exon 7. The 5’ and 3’ untranslated regions are shown as white boxes. ECD, extracellular domain; TMD, transmembrane
domain; ICD, intracellular domain.
doi:10.1371/journal.pone.0119459.g001
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Substantial amounts of coronary artery and aortic calcification were defined as>100 mg and
>600 mg, respectively, as previously reported [2]. The RTRs were followed up for a mean dura-
tion of 4.4 ± 0.3 years and underwent repeat measurement of aortic and coronary artery Agat-
ston scores by spiral CT scanning, and assessment of cardiovascular event incidence and
mortality, as described [23].
Genotyping CASR gene polymorphisms
Six CASR polymorphisms were selected for analysis. Three SNPs (rs115759455, rs7652589 and
rs1501899) were located in the promoter region of the CASR and three were non-synonymous
SNPs located in the coding region of exon 7 (A986S (rs1801725), R990G (rs1042636) and
Q1011E (rs1801726)) (Fig. 1). These six SNPs were genotyped using leukocyte DNA obtained
from 284 RTRs, as described [11] and using the following PCR primers (promoter 1 forward:
TGAACCTCTACAGCCCTTCG, promoter 1 reverse: GGCAATGTAAAGCGGAAAAA; pro-
moter 2 forward: GTGGTCAGTGAGGGAGAGGA, promoter 2 reverse: GGCATGGAGT
GAGGGTACAT; exon 7 forward: CAGAAGGTCATCTTTGGCAGCGGCA, exon 7 reverse:
TCTTCCTCAGAGGAAAGGAGTCTGG). All SNPs were analysed by Sanger sequencing of a
PCR-product amplified using the BigDye Terminator v3.1 Cycle Sequencing Kit (Life Technol-
ogies, Grand Island, NY) and an automated detection system (ABI 3730 Automated capillary
sequencer; Applied Biosystems) [24]. Departure from the Hardy-Weinberg equilibrium was
determined by Chi-squared analysis (X2). Observed SNP allele frequencies in the study cohort
were compared to SNP frequencies of the National Heart, Lung and Blood Institute Exome Se-
quencing Project ((NHLBI-ESP) http://evs.gs.washington.edu/EVS/) and the 1000 Genomes
Project (http://www.1000genomes.org/) [25, 26]. Haplotype frequencies were estimated by the
maximum likelihood method using Haplotyper software [27]. Linkage disequilibrium was cal-
culated using Haploview v4.2.
Statistical analysis
Analyses were performed using IBM SPSS version 20 software. Association analyses were con-
ducted between CASR SNPs and baseline clinical and biochemical parameters. Radiological pa-
rameters measured at baseline and after a mean follow-up period of 4.4 ± 0.3 years were
included in the analysis. Parameters showing a right skewed distribution were log transformed
prior to parametric analyses. The power of the study was determined using the web-based pro-
gram QUANTO v1.2 [28]. A univariate analysis of associations was performed using Pearson’s
cross product correlation and Chi-squared test for continuous and categorical variables, re-
spectively [11]. All variables that showed associations at the P0.2 statistical level, following
Bonferroni correction, were entered into a stepwise multivariate linear regression model and
an assessment of confounding variables was performed. Kaplan-Meier curves were used to ana-
lyse the impact of CASR SNPs on all-cause mortality and cardiovascular event free survival and
compared by the Mantel (log-rank) test [29]. Results are presented as mean ± SD, or number
of patients (N (%)), as appropriate. The results of the multivariate analysis are presented as re-
gression coefficient (B) values ± 95% confidence interval (CI). A value of P<0.05 was consid-
ered significant for all analyses.
Results
Patient characteristics
At baseline, the study cohort comprised 284 adult RTRs (168 males and 116 females) of Euro-
pean origin, with a mean ± SD age of 52.8 ± 12.6 years (Table 1). The patients had a moderate
CASR SNPs and Vascular Calcification
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reduction of kidney function (CKD stage II-IIIa), explained by the post-renal transplant status,
and the mean concentrations of serum biochemical markers of mineral metabolism, glucose
and total cholesterol were within normal limits (Table 1). Hyperparathyroidism (defined as
serum PTH concentrations>6.5 pmol/L), hyperphosphataemia (defined as serum phosphate
concentrations>1.50 mmol/L) and diabetes affected 25%, 9% and 15% of the study cohort, re-
spectively (Table 1). Baseline assessment of arterial calcification by spiral CT scanning in 266
RTRs revealed substantial amounts of CAC (>100 mg hydroxyapatite) and AoC (>600 mg hy-
droxyapatite) in>20% and>35% of individuals, respectively (Table 1). Follow-up CAC and
AoC spiral CT assessments, after a mean period of 4.4 ± 0.3 years, in 187 individuals revealed
>50% of patients to have an increase in CAC or AoC, with 30% of patients having experienced
1 cardiovascular events, with an overall mortality rate for the cohort of 12%.
Table 1. Baseline clinical, biochemical and radiological characteristics of the Brussels Renal
Transplant Cohort.
Parameter Value
Clinical (N = 284)
Age (years) 52.8 ± 12.6
Gender (males) 168 (59%)
Body mass index (kg/m2) 26.4 ± 4.8
Years after kidney graft 7.8 ± 6.3
Parathyroidectomised subjects 44 (16%)
Systolic blood pressure (mmHg) 136 ± 20
History of smoking 152 (54%)
Patients with hyperparathyroidism 70 (25%)
Patients with hyperphosphataemia 26 (9%)
Patients with diabetes mellitus 43 (15%)
Serum (N = 284)a
Creatinine (μmol/L) 122 ± 58
Estimated glomerular ﬁltration rate (ml/min/1.73 m2) 56 ± 24
Glucose (mmol/L) 5.7 ± 2.2
Total cholesterol (mmol/L) 5.3 ± 1.1
Total calcium (mmol/L) 2.4 ± 0.1
Phosphate (mmol/L) 1.0 ± 0.2
Intact parathyroid hormone (pmol/L) 5.7 ± 4.6
25-hydroxyvitamin D (nmol/L) 42.8 ± 24.4
1,25-dihydroxyvitamin D (pmol/L) 86.7 ± 43.3
Radiological (N = 266)
Aortic calciﬁcation score (AgS) 3309 ± 7101
Coronary artery calciﬁcation score (AgS) 939 ± 1600
Number of patients with aortic calciﬁcation >600mg 63 (24%)
Number of patients with coronary artery calciﬁcation >100mg 99 (37%)
Results are presented as mean ± SD or the number of patients with the % of the total of number of patients
shown in parentheses. AgS, Agatston score.
aNormal serum ranges: creatinine, 53–124 μmol/L; glucose, 3.8–6.1 mmol/L; total cholesterol, <5.0 mmol/L;
total calcium, 2.10–2.50 mmol/L; phosphate, 0.77–1.50 mmol/L; intact parathyroid hormone, 1.0–6.5 pmol/L;
25-hydroxyvitamin D, 75–250 nmol/L; 1,25-dihydroxyvitamin D, 47–117 pmol/L.
doi:10.1371/journal.pone.0119459.t001
CASR SNPs and Vascular Calcification
PLOS ONE | DOI:10.1371/journal.pone.0119459 March 18, 2015 5 / 14
CASR SNP frequencies in renal transplant recipients
Six CASR SNPs were selected for an assessment of genotype and allele frequencies (Fig. 1 and
Table 2). Three of these SNPs are coding region variants (A986S, R990G and Q1011E), and the
other three SNPs are located in the promoter region (rs7652589, rs1501899 and rs115759455).
The promoter region SNP, rs115759455, has not been previously reported and was detected in
this patient cohort during the study. The allelic frequencies of these six CASR SNPs (Table 2)
were not significantly different to those observed in large Caucasian population cohorts such as
the NHLBI-ESP and 1000 Genomes Project cohorts [25, 26]. Furthermore, the allelic frequen-
cies of these six CASR SNPs did not deviate from the Hardy-Weinberg equilibrium (Table 2).
Linkage disequilibrium was observed between the rs1501899 and rs7652589 promoter region
SNPs (r2 = 0.79), but not between the other CASR variants (r2<0.015).
Association of CASR SNPs with serum glucose, indices of mineral
metabolism, arterial calcification scores and clinical outcomes
Investigations for associations between individual CASR variants and arterial calcification
scores, systolic blood pressure, serum glucose, serum total cholesterol and serum markers of
mineral metabolism (Table 3) revealed an association between CASR SNPs and serum metabo-
lites, but not directly with cardiovascular disease. Thus, univariate analysis revealed a signifi-
cant association between the A986S and serum glucose concentrations (Table 3). The mean
glucose concentration of patients that were homozygous for the major allele A986 allele (AA;
N = 216) was 5.7 ± 2.1 mmol/L compared with 8.7 ± 5.4 mmol/L for patients that were homo-
zygous for the S986 minor allele (SS; N = 6) (P<0.05). All patients were taking prednisolone as
part of their immunosuppressant regimen. However, differences in the cumulative dosage of
this glucocorticoid medication did not significantly affect serum glucose concentrations in the
study cohort (S1 Table).
The CASR SNPs were not significantly associated with AoC or CAC scores at baseline, or
with progression of arterial calcification, or the occurrence of cardiovascular events during the
study follow-up period (Table 4). Univariate subgroup analyses that excluded patients with dia-
betes, hyperparathyroidism or hyperphosphataemia, as these factors are key determinants of
Table 2. CASR polymorphism genotype and allele frequencies in the Brussels Renal Transplant Cohort.
SNP ID Location Nucleotide
substitution
Amino acid
substitution
Genotype
frequencies
Allele
frequencies
Hardy-Weinberg
equilibrium
rs115759455 5’ UTR (c.-
83867)
C > T - 0.91/0.08/0.01 0.95/0.05 X2 = 3.13 (P = 0.08)
rs7652589 5’ UTR (c.-
83707)
G > A - 0.41/0.44/0.15 0.63/0.37 X2 = 1.12 (P = 0.28)
rs1501899 5’ UTR (c.-
65467)
G > A - 0.42/0.45/0.13 0.64/0.36 X2 = 0.44 (P = 0.51)
rs1801725 Exon 7
(c.2956)
G > T A986S 0.76/0.22/0.02 0.87/0.13 X2 = 0.56 (P = 0.45)
rs1042636 Exon 7
(c.2968)
A > G R990G 0.88/0.11/0.01 0.94/0.06 X2 = 0.87 (P = 0.35)
rs1801726 Exon 7
(c.3031)
C > G Q1011E 0.93/0.07/0.0 0.97/0.03 X2 = 0.38 (P = 0.54)
Genotype frequencies are provided for homozygous major alleles, heterozygous alleles, and homozygous minor alleles, respectively in N = 284 subjects.
Allelic frequencies are provided for major and minor alleles, respectively. UTR, untranslated region.
doi:10.1371/journal.pone.0119459.t002
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vascular calcification [30–32], also did not reveal any association between CASR SNPs and
AoC or CAC scores (S2–S4 Tables). Furthermore, an analysis of CASR SNP genotypes in RTRs
stratified according to the presence of low or high arterial calcification scores did not reveal
any significant associations (Table 5). Using the Kaplan-Meier curve estimate, the effect of
CASR variants on all-cause mortality was assessed and was shown to be absent for all the CASR
SNPs (data not shown, P>0.05). An analysis of associations between multi-locus CASR haplo-
types and serum glucose, indices of mineral metabolism and arterial calcification scores, was
not performed due to the low prevalence of minor alleles in these haplotypes.
Table 5. Comparison of CASR SNP genotypes in patients with low and high levels of aortic calciﬁcation (AoC) and coronary artery calciﬁcation
(CAC).
AoC CAC
<600mg >600mg <100mg >100mg
rs115759455
CC 185 (91%) 60 (95%) 151 (90%) 94 (95%)
CT 17 (8%) 3 (5%) 15 (9%) 5 (5%)
TT 2 (1%) 0 2 (1%) 0
P - 1.0 - 1.0
rs7652589
GG 88 (43%) 22 (35%) 74 (44%) 36 (36%)
GA 81 (40%) 35 (56%) 63 (38%) 53 (54%)
AA 35 (17%) 6 (10%) 31 (18%) 10 (10%)
P - 0.40 - 0.15
rs1501899
GG 88 (43%) 24 (38%) 73 (43%) 39 (39%)
GA 84 (41%) 35 (56%) 66 (39%) 53 (39%)
AA 32 (16%) 4 (6%) 29 (17%) 7 (39%)
P - 0.36 - 0.11
A986S
AA 158 (77%) 47 (75%) 127 (%) 78 (79%)
AS 40 (20%) 16 (25%) 38 (%) 12 (12%)
SS 6 (3%) - 3 (%) 3 (3%)
P - 1.0 - 1.0
R990G
RR 176 (86%) 59 (94%) 147 (88%) 88 (89%)
RG 26 (13%) 4 (6%) 19 (11%) 11 (11%)
GG 2 (1%) - 2 (1%) -
P - 1.0 - 1.0
Q1011E
QQ 192 (94%) 58 (92%) 159 (95%) 91 (92%)
QE 12 (6%) 5 (8%) 9 (5%) 8 (8%)
EE - - - -
P - 1.0 - 1.0
Results are shown as N (%). P-values (P) represent a Chi-squared analysis of the <600mg AoC group (N = 204) versus the >600mg AoC group (N = 63)
and <100mg CAC group (N = 168) versus the >100mg CAC group (N = 99), respectively. All values are shown following Bonferroni correction. −,
indicates values not provided. The genotypic alleles of the A986S, R990G and Q1011E coding region SNPs are represented by amino acids.
doi:10.1371/journal.pone.0119459.t005
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Following Bonferroni correction, all parameters that had associations at the P0.2 statisti-
cal level were entered into a stepwise multivariate linear regression model, which corrected for
potentially confounding influences (Table 6). The homozygous S986 allele continued to remain
significantly associated with serum glucose after correcting for the presence of diabetes, as well
as correcting for age, gender, body mass index (BMI), renal function, glucocorticoid and im-
munosuppressant usage, and transplantation vintage (Table 6). A significant association was
also observed between the promoter region CASR SNP, rs115759455, and serum phosphate
concentrations after correcting for confounding parameters such as calcium and vitamin D
supplementation, serum creatinine and estimated glomerular filtration rate, serum calcium,
1.25-dihydroxyvitamin D and intact PTH concentrations. Thus, the mean serum phosphate
concentration in patients homozygous for the rs115759455 major allele (CC) was 1.00 ± 0.23
mmol/L (N = 258) and 1.14 ± 0.31 mmol/L for patients harbouring the CT alleles (N = 23,
P<0.05).
Discussion
Our study has revealed that the A986S CASR SNP is a predictor of serum glucose concentra-
tions independently of BMI and the presence of diabetes mellitus. Thus, patients who were ho-
mozygous for the S986 minor allele had elevations in serum glucose, and this highlights a
potential role for the CaSR as a regulator of systemic glucose homeostasis. Indeed, this would
be consistent with the reported expression of the CaSR in pancreatic islet beta-cells and that
CaSR activation by extracellular calcium or calcimimetic drugs in isolated islets can stimulate
beta-cell activity and insulin secretion [33–35]. In addition, the CaSR is expressed and func-
tionally active in adipocytes [36], and may potentially regulate the peripheral actions of insulin,
as highlighted by the finding of an association with the A986S CASR polymorphism and insu-
lin resistance in patients with the polycystic ovarian syndrome [37]. Moreover, altered CaSR
Table 6. Signiﬁcant determinants of serum glucose and phosphate concentrations.
Step number Parameter B 95% CI P
Glucose
1 Diabetes 0.203 0.166 to 0.240 <0.0001
2 A986S (SS) 0.126 0.039 to 0.214 <0.05
Phosphate
1 eGFR -0.147 -0.208 to -0.086 <0.0001
2 Calcium -0.851 -1.259 to -0.422 <0.0001
3 1,25-dihydroxyvitamin D -0.077 -0.123 to -0.030 0.001
4 rs115759455 (CT) 0.051 0.009 to 0.093 <0.05
5 Parathyroid hormone -0.049 -0.088 to -0.010 <0.05
All parameters scoring P 0.2 in univariate analyses underwent multivariate modelling and correction for the inﬂuence of potentially confounding
parameters. Confounding parameters for serum glucose concentration entered into the multivariate stepwise linear regression model were gender, the
presence of diabetes, age, body mass index, glucocorticoid and tacrolimus therapy, and transplantation vintage. Serum phosphate concentrations were
adjusted for the effect of estimated glomerular ﬁltration rate (eGFR), creatinine, calcium, 1,25-dihydroxyvitamin D, gender, parathyroid hormone
concentrations, and calcium and vitamin D supplementation. Multivariate modelling demonstrated the presence of diabetes and the homozygous minor
allele of the A986S SNP as independent predictors of serum glucose concentrations. Estimated GFR, serum calcium, parathyroid hormone, 1,25-
dihydroxyvitamin D concentrations and the heterozygous form of the rs115759455 SNP were revealed to be independent predictors of serum phosphate
concentrations. P-values (P) are displayed following Bonferroni correction. B, regression coefﬁcient; CI, conﬁdence interval.
doi:10.1371/journal.pone.0119459.t006
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function in diabetic patients may contribute to the development of atherosclerosis and in-
creased cardiovascular risk [38].
A significant association was also observed with the rs115759455 5’UTR CASR SNP and in-
creased serum phosphate concentrations. Common genetic variants have been previously
linked to serum phosphate concentrations, including a SNP (rs17265703) located on chromo-
some 3q21.1, which was shown to be in strong linkage disequilibrium with the A986S CASR
variant [39]. Our study revealed the rs115759455 minor CASR allele (T) to be an independent
predictor of serum phosphate concentrations, as heterozygosity (TC), when compared to ho-
mozygosity (CC) for the major allele, was associated with significantly increased serum phos-
phate concentrations; such effects of homozygosity (TT) for the minor allele could not be
established as only two RTRs were homozygous. Circulating phosphate concentrations are reg-
ulated by the actions of PTH and fibroblast growth factor-23 (FGF-23) on phosphate reabsorp-
tion by the proximal renal tubule, and by 1,25-dihydroxyvitamin D mediated intestinal
phosphate reabsorption [40]. Our findings indicate that the CaSR may regulate phosphate ho-
meostasis independently of its effects on circulating PTH and 1,25-dihydroxyvitamin D con-
centrations. Moreover, studies of mice with the combined ablation of Casr and Pth alleles
indicate that such effects of the CaSR on phosphate homeostasis are also not mediated by FGF-
23 [41]. Indeed, the CaSR is likely to have a direct role in regulating circulating phosphate con-
centrations, as highlighted by micro-perfusion studies of isolated proximal renal tubules,
which have revealed CaSR activation in this nephron segment to promote renal phosphate re-
absorption [42]. Our findings provide further support for the CaSR being an independent regu-
lator of phosphate metabolism.
However, CASR SNPs were not significantly associated with the development and progres-
sion of aortic medial calcification or coronary arterial intimal calcification, or cardiovascular
outcomes in RTRs. These findings contrast with a report of the A986S CASR SNP as an inde-
pendent predictor of coronary artery disease and cardiovascular mortality [22]. In addition, a
mouse model, Nuf, with an activating Casrmutation, has been reported to have mineralisation
within the aorta, elastic and muscular arteries [43]. The differences in these studies may be
partly explained by differences in the cohort characteristics e.g. patient age, ethnicity, medica-
tion history, and underlying pathologies of the different patient groups (renal transplant versus
non-renal disease); as well as by species differences (man versus mouse). However, these differ-
ences may also reflect limitations in our study of the cohort of RTRs, which include the small
sample size and low prevalence of some alleles. Moreover, these findings may be affected by
survival bias, which favours patients with less severe cardiovascular disease and calcification.
Our study of 284 RTRs had a power of 99% and 89% to detect a locus that contributed 10% or
5%, respectively, of the genetic variance, assuming a type 1 error of 0.01 and marker frequency
of 0.2. This indicates that our study was sufficiently powered to detect effects that would ex-
plain up to 5% of the variance, but not 1% of variance [28]. Nevertheless, the findings of this
study indicate that the six common CASR polymorphisms are unlikely to play a major role in
the development or progression of aortic or coronary artery calcification in patients with
renal transplants.
In conclusion, our investigation of associations between common CASR variants, arterial
calcification and other cardiovascular risk factors in a cohort of renal transplant recipients indi-
cates that these CASR variants are unlikely to represent major determinants for calcification of
either the aorta or coronary arteries. However, the CaSR was demonstrated to be an indepen-
dent predictor of serum glucose and phosphate concentrations, thereby highlighting potential
new metabolic roles for this GPCR.
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